Sebelipase Alfa Drug Asset Due Diligence Report 2026

This Sebelipase Alfa Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Sebelipase Alfa can convert its Enzyme profile and LIPA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Sebelipase Alfa (query alias: sebelipase alfa)
Modality / target	Enzyme; LIPA; LIPA modulators
Highest global status	Approved
Originator	Alexion Pharmaceuticals, Inc.
Active developers	Alexion Europe SAS, AstraZeneca PLC, Immune Disease Institute, Inc.

The MCP disease footprint includes Cholesterol Ester Storage Disease, Wolman Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT01757184	Phase 3	Completed	66	Percentage Of Participants Achieving Alanine Aminotransferase Normalization
NCT02112994	Phase 2	Completed	31	Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)
NCT02193867	Phase 2	Terminated	10	Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Long-term Sebelipase Alfa Treatment in Children and Adults With Lysosomal Acid Lipase Deficiency

Phase 2; n=31; evaluation: Positive. Reported fields: ADAs = positive 2 pts ; ADAs = positive 2 pts

Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study

Phase 3; n=59; evaluation: Positive. Reported fields: Alanine aminotransferase(normalize) = 47 %

Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study

Phase 2; n=8; evaluation: Positive. Reported fields: -; IRR = 2 Participant

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Sebelipase Alfa addresses Cholesterol Ester Storage Disease, Wolman Disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Enzyme—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: LIPA records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2022-06-06	EtiraRx's Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Methods of desensitizing against infusion associated reactions in lysosomal acid lipase deficiency (LAL-d) patients treated with exogenous lysosomal acid lipase (lal”. The milestone feed surfaced a patent-application signal described as “Methods for reducing liver fibrosis and treating lysosomal acid lipase deficiency in patients based on ishak fibrosis stage”. The milestone feed surfaced a patent-application signal described as “Lysosomal acid lipase deficiency compositions and methods”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO